GSK to pay 23andMe $20m to access consumer DNA data

GSK will pay 23andMe $20 million for access to the genetic-testing company’s vast trove of consumer DNA data, extending a five-year collaboration that’s allowed the drug maker to mine genetic data as it researches new medications. Under the new agreement, 23andMe will provide GSK with one year of access to anonymized DNA data from the approximately 80 percent of gene-testing customers who have agreed to share their information for research, 23andMe said in a statement Monday.